Biomarker Book Cites Cleanascite™ To Study Body Fluids

MONMOUTH JUNCTION, N.J. - March 30, 2019 - PRLog -- Biotech Support Group reports on a recent book chapter describing the simplicity and efficiency of their lipid clearance sample preparation technology for reducing analytical variables in the proteomic comparison of body fluids. The citation is:

Farina, Annarita. "Pre-fractionation of Noncirculating Biological Fluids to Improve Discovery of Clinically Relevant Protein Biomarkers (https://link.springer.com/protocol/10.1007/978-1-4939-9164-8_2)." Proteomics for Biomarker Discovery. Humana Press, New York, NY, 2019. 23-37.

For proteomic biomarker discovery, it is necessary to bridge the gap between basic and applied research by complying with clinical requirements. This chapter provides key suggestions for improving the discovery of clinically relevant protein biomarkers from body fluids. The chapter states : "If the elimination of lipids…is necessary, the sample can be treated with lipid removal (Cleanascite)…"

"I am pleased that Cleanascite™ is cited as a general delipidation reagent for all the different body fluids that can be compared within a proteomic analysis for the discovery of new biomarkers." states Swapan Roy, Ph.D., President and Founder of Biotech Support Group.

For more information visit: Cleanascite™ Lipid Removal Reagent and Clarification, at
http://www.biotechsupportgroup.com/Cleanascite-Lipid-Removal-Reagent-p/x2555.htm

About Biotech Support Group LLC

Converging with cultural and technological disruptions forthcoming in healthcare, Biotech Support Group develops methods for cost effective and efficient sample prep essential for these expanding markets. Following a tiered business strategy, the company continues its growth in the consumable research products area supporting the rapidly expanding installation of LC-MS instrument and computational infrastructure. For this market, key products include: AlbuVoid™ and AlbuSorb™ for albumin depletion, Cleanascite™ for lipid adsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal, and NuGel™ for functional proteomics. From these innovations, the company has acquired knowledgebase and biomarker intellectual property assets that support discoveries of protein markers from blood, with special emphasis on early detection and personalized medical decisions for cancer patients. For more information, go to http://www.biotechsupportgroup.com.

Contact:
Matthew Kuruc
732-274-2866, mkuruc@biotechsupportgroup.com